Provided by Tiger Trade Technology Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

16.95
+2.5717.87%
Post-market: 16.81-0.1400-0.83%19:59 EDT
Volume:15.77M
Turnover:257.10M
Market Cap:2.55B
PE:-3.78
High:18.24
Open:14.24
Low:13.00
Close:14.38
52wk High:18.57
52wk Low:7.48
Shares:150.42M
Float Shares:117.99M
Volume Ratio:6.13
T/O Rate:13.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4800
EPS(LYR):-6.8648
ROE:-799.46%
ROA:-71.98%
PB:208.60
PE(LYR):-2.47

Loading ...

Biohaven Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 14

Morgan Stanley Cuts Price Target on Biohaven to $18 From $21, Keeps Overweight Rating

MT Newswires Live
·
May 13

Biohaven (BHVN) Valuation Check After Q1 Results And New Shelf Registration

Simply Wall St.
·
May 12

Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures

TIPRANKS
·
May 06

Biohaven launches USD 350 million at-the-market share offering program

Reuters
·
May 06

Stock Track | Biohaven Pharmaceutical Plummets 5.23% Intraday After Multiple Analyst Price Target Cuts

Stock Track
·
May 05

RBC Cuts Price Target on Biohaven to $22 From $23, Keeps Outperform, Speculative Risk

MT Newswires Live
·
May 05

Biohaven price target lowered to $12 from $14 at BofA

TIPRANKS
·
May 05

Biohaven Ltd Files for Offering of up to $350 Mln Common Shares - SEC Filing

THOMSON REUTERS
·
May 05

Biohaven files automatic mixed securities shelf

TIPRANKS
·
May 05

Biohaven Q1 Adj. EPS $(0.69) Beats $(0.78) Estimate

Benzinga Earnings
·
May 05

BRIEF-Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing

Reuters
·
May 05

Biohaven Q1 FY26 net loss narrows to $130.53 million; R&D expense drops 44.67% to $103.83 million

Reuters
·
May 05

Biohaven holds annual shareholder meeting, elects directors to board

Reuters
·
May 05

Biohaven Ltd - Q1 Non-Gaap Adj Net Loss $102.2 Mln, or $0.69 per Share

THOMSON REUTERS
·
May 05

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 05

Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio

Simply Wall St.
·
May 03

Assessing Biohaven (BHVN) Valuation After Sharp One Month Rebound And Steep One Year Decline

Simply Wall St.
·
Apr 23

Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial

Simply Wall St.
·
Apr 03

Biohaven Is Maintained at Buy by Citigroup

Dow Jones
·
Apr 02